Literature DB >> 28249706

Preincubation-dependent and long-lasting inhibition of organic anion transporting polypeptide (OATP) and its impact on drug-drug interactions.

Yoshihisa Shitara1, Yuichi Sugiyama2.   

Abstract

Preincubation with cyclosporin A (CsA), a potent inhibitor of organic anion transporting polypeptide 1B1 (OATP1B1) and OATP1B3, enhanced its inhibitory effects on these transporters in vitro. A similar effect was observed upon preincubation with some other inhibitors. Removing these from the incubation media did not readily reverse the inhibition on OATP1B1 and OATP1B3. This preincubation-dependent long-lasting inhibition appeared to be related to CsA concentration in the cells in addition to that in the incubation media. Thus, we hypothesized that CsA inhibits OATP1B1 and OATP1B3 from inside (trans-inhibition) as well as outside (cis-inhibition) the cells and constructed the cis- and trans-inhibition model. The enhanced inhibitory effect of CsA on OATP1B1 observed after preincubation was quantitatively described using Ki,out and Ki,in as inhibition constants for cis- and trans-inhibitions, respectively. In addition, a long-lasting inhibition was also described by this model. Additional factors taken into consideration when simulating in vivo pharmacokinetic alterations by CsA are potential inhibition by AM1, a major metabolite of CsA, which has been reported to inhibit OATP1B1 and OATP1B3. Based on the physiologically based pharmacokinetic model incorporating trans- and cis-inhibition of OATP1B1 by CsA, the simulation showed that OATP1B1-mediated drug-drug interaction with CsA was suggested to be time-dependent also in vivo although further clinical studies are required for confirmation.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Drug–drug interactions; Hepatic uptake; Long-lasting inhibition; Modeling & simulation; OATP1B1; Physiologically based pharmacokinetic model; Time-dependent inhibition

Mesh:

Substances:

Year:  2017        PMID: 28249706     DOI: 10.1016/j.pharmthera.2017.02.042

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  11 in total

1.  Preincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1- and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions.

Authors:  Taleah Farasyn; Alexandra Crowe; Oliver Hatley; Sibylle Neuhoff; Khondoker Alam; Jean Kanyo; TuKiet T Lam; Kai Ding; Wei Yue
Journal:  J Pharm Sci       Date:  2019-04-30       Impact factor: 3.534

2.  Multiple circulating saponins from intravenous ShenMai inhibit OATP1Bs in vitro: potential joint precipitants of drug interactions.

Authors:  Olajide E Olaleye; Wei Niu; Fei-Fei Du; Feng-Qing Wang; Fang Xu; Salisa Pintusophon; Jun-Lan Lu; Jun-Ling Yang; Chuan Li
Journal:  Acta Pharmacol Sin       Date:  2018-10-16       Impact factor: 6.150

3.  In Vitro Assessment of Transporter Mediated Perpetrator DDIs for Several Hepatitis C Virus Direct-Acting Antiviral Drugs and Prediction of DDIs with Statins Using Static Models.

Authors:  Xiaoyan Chu; Grace Hoyee Chan; Robert Houle; Meihong Lin; Jocelyn Yabut; Christine Fandozzi
Journal:  AAPS J       Date:  2022-03-21       Impact factor: 4.009

4.  Novel in Vitro Method Reveals Drugs That Inhibit Organic Solute Transporter Alpha/Beta (OSTα/β).

Authors:  Melina M Malinen; Antti Kauttonen; James J Beaudoin; Noora Sjöstedt; Paavo Honkakoski; Kim L R Brouwer
Journal:  Mol Pharm       Date:  2018-12-14       Impact factor: 4.939

5.  Comparative Study of the Dose-Dependence of OATP1B Inhibition by Rifampicin Using Probe Drugs and Endogenous Substrates in Healthy Volunteers.

Authors:  Issey Takehara; Takashi Yoshikado; Keiko Ishigame; Daiki Mori; Ken-Ichi Furihata; Nobuaki Watanabe; Osamu Ando; Kazuya Maeda; Yuichi Sugiyama; Hiroyuki Kusuhara
Journal:  Pharm Res       Date:  2018-05-10       Impact factor: 4.200

Review 6.  Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions.

Authors:  Khondoker Alam; Alexandra Crowe; Xueying Wang; Pengyue Zhang; Kai Ding; Lang Li; Wei Yue
Journal:  Int J Mol Sci       Date:  2018-03-14       Impact factor: 5.923

7.  Quantitative Prediction of OATP-Mediated Drug-Drug Interactions With Model-Based Analysis of Endogenous Biomarker Kinetics.

Authors:  Kenta Yoshida; Cen Guo; Rucha Sane
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-08-23

8.  Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions.

Authors:  Tatsuki Mochizuki; Maciej J Zamek-Gliszczynski; Kenta Yoshida; Jialin Mao; Kunal Taskar; Hideki Hirabayashi; Xiaoyan Chu; Yurong Lai; Tadayuki Takashima; Kevin Rockich; Yoshiyuki Yamaura; Kaku Fujiwara; Tadahaya Mizuno; Kazuya Maeda; Kenichi Furihata; Yuichi Sugiyama; Hiroyuki Kusuhara
Journal:  Clin Pharmacol Ther       Date:  2022-04-11       Impact factor: 6.903

Review 9.  Regulation of Drug Transport Proteins-From Mechanisms to Clinical Impact: A White Paper on Behalf of the International Transporter Consortium.

Authors:  Kim L R Brouwer; Raymond Evers; Elizabeth Hayden; Shuiying Hu; Cindy Yanfei Li; Henriette E Meyer Zu Schwabedissen; Sibylle Neuhoff; Stefan Oswald; Micheline Piquette-Miller; Chitra Saran; Noora Sjöstedt; Jason A Sprowl; Simone H Stahl; Wei Yue
Journal:  Clin Pharmacol Ther       Date:  2022-05-24       Impact factor: 6.903

Review 10.  Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations.

Authors:  Kunal S Taskar; Venkatesh Pilla Reddy; Howard Burt; Maria M Posada; Manthena Varma; Ming Zheng; Mohammed Ullah; Arian Emami Riedmaier; Ken-Ichi Umehara; Jan Snoeys; Masanori Nakakariya; Xiaoyan Chu; Maud Beneton; Yuan Chen; Felix Huth; Rangaraj Narayanan; Dwaipayan Mukherjee; Vaishali Dixit; Yuichi Sugiyama; Sibylle Neuhoff
Journal:  Clin Pharmacol Ther       Date:  2019-12-31       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.